Nucala is manufactured by GlaxoSmithKline (GSK) [1].
What is Nucala used for?
Nucala is a prescription medication used to treat severe eosinophilic asthma in adults and children 12 years and older. It is also approved for treating eosinophilic granulomatosis with polyangiitis (EGPA) in adults and for treating certain patients 6 years and older with chronic rhinosinusitis with nasal polyps (CRSwNP) [2].
How does Nucala work?
Nucala’s active ingredient is mepolizumab, a monoclonal antibody that works by targeting and reducing the level of eosinophils in the body [1][2]. Eosinophils are a type of white blood cell that can contribute to inflammation in conditions like severe asthma and EGPA [2].
When does Nucala's patent expire?
Patent expiration dates for medications can be complex and are subject to various factors including patent challenges and extensions. Information on specific patent timelines for Nucala can be found on resources like DrugPatentWatch.com [3].
What are the side effects of Nucala?
Common side effects of Nucala include headaches, injection site reactions, and back pain [2]. It is important to note that this is not a complete list of all potential side effects, and individuals should discuss any concerns with their healthcare provider [2].
Are there alternatives to Nucala for severe asthma?
Other biologic medications are available for the treatment of severe asthma, targeting different pathways involved in the disease. These may include drugs that target IL-5, IL-4, IL-13, or IgE. The choice of treatment depends on the individual patient's specific disease characteristics and exacerbation history [4].
How is Nucala administered?
Nucala is administered as an injection, typically by a healthcare professional or by the patient at home after training [2]. The dosing frequency varies depending on the condition being treated [2].
Sources:
[1] https://www.gsk.com/
[2] https://www.nucala.com/
[3] https://www.drugpatentwatch.com/
[4] https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6302051/